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Despite progress made in both the basic knowledge of
many infectious diseases and the process of drug discovery
and development, tropical infectious diseases such as
malaria, leishmaniasis, lymphatic filariasis, Chagas’
disease, and schistosomiasis continue to cause significant
morbidity and mortality, mainly in the developing world.
The burden of infectious diseases has been compounded
by the re-emergence of diseases such as tuberculosis,
dengue, and African trypanosomiasis. These diseases all
predominantly affect poor populations in the less-
developed world.1
WHO has identified three key factors that can
collectively contribute to the burden of illness associated
with infectious diseases: failure to use existing tools
effectively, inadequate or non-existent tools, and
insufficient knowledge of the disease.2 The discovery and
development of most of the current tropical
pharmacopoeia was driven by colonial requirements
during the first part of the 20th century.3 As Western
interests drifted away from these regions, tropical diseases
have become progressively neglected, mainly because they
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do not offer sufficient financial returns for the
pharmaceutical industry to engage in research and
development. Tuberculosis—another major poverty-
related disease—is also neglected in terms of drug
research and development.
Despite an ever-increasing need for safe, effective, and
affordable medicines for the treatment of these diseases,
drug development has virtually stopped.4,5 We present an
analysis of the trends in drug development over the past
25 years, focusing particularly on neglected diseases, and
review future prospects for stimulating research and
development through analysis of current public and
private sector initiatives aimed at correcting this
imbalance in research and development.
Drug development over the past 25 years
We did a quantitative and qualitative analysis of global
drug development output over the past 25 years, focusing
specifically on neglected diseases. Data on the new
chemical entities marketed in this period were compiled
by searches of Medline and databases of the US Food and
Drug Administration and the European Agency for the
Evaluation of Medicinal Products. The data are presented
over time and by therapeutic class, indicating innovation
level and market share in both absolute terms and relative
to the burden of disease expressed as millions of disability-
adjusted life-years (DALYs). Although rare, examples of
registrations exclusively within developing countries do
exist—eg, artemisinin derivatives for malaria developed
and manufactured in China.
We found that 1393 new chemical entities were granted
a market authorisation between 1975 and 1999 (table 1).
Their quantitative distribution in different therapeutic
areas shows a bias towards high-income countries. This
imbalance was especially pronounced for infectious and
parasitic diseases, which account for a third of the
worldwide disease burden but only 5% of the disease
burden in high-income countries. To quantify the level of
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0·313 throughout the whole period (table 2). The
innovation index is defined as the number of group 1 new
chemical entities per total number of new chemical
entities, where group 1 drugs have a substantial and
important gain over existing therapies (eg, breakthrough
drugs), and group 2 drugs offer little or no therapeutic
gain (eg, “me-too” drugs). In other words, 68·7% (959
new chemical entities) of the 1393 registered products
present little or no therapeutic gain compared with what
was already available. Conversely, the innovation index
for neglected diseases is 1, indicating that when the
development attention is limited, only innovative drugs
are developed. Moreover, all of the 16 newly developed
drugs for neglected diseases have been included in the
latest WHO Essential Drugs List, whereas less than 2%
(21) of all other drugs were included in this list. Overall,
despite vast scientific and technological advances in the
processes and organisation of drug research and
development, no significant increase in the number of
drugs delivered or improvement in the degree of
innovation has been seen.
Table 3 lists drugs currently under clinical investig-
ation. We found some activity for malaria, leishmaniasis,
onchocerciasis, lymphatic filariasis, tuberculosis, schistos-
omiasis, and leprosy, but no clinical development activity
for other neglected diseases (eg, African trypanosomiasis,
Chagas’ disease, and dengue). Of all drugs in develop-
PUBLIC HEALTH
THE LANCET • Vol 359 • June 22, 2002 • www.thelancet.com 2189
neglect, we calculated the ratio of the number of new
drugs marketed and the disease burden for major disease
categories. For the period considered, the number of new
chemical entities per million DALYs was 0·55 for
infectious and parasitic diseases, compared with values
two to three times higher (ranging between 1·25 and 1·44)
for the main diseases of the high-income countries. The
ratio for all infectious diseases combined was mostly
accounted for by 20 antiretroviral drugs developed in the
past 5–15 years, the development of which benefited from
a serious political commitment from wealthy countries, as
well as major investment from the pharmaceutical
industry that was motivated by the high potential return
on investment in high-income countries.6 For tuberculosis
and malaria, the numbers of new chemical entities per
million DALYs are as low as 0·1.
We examined specifically registration of new chemical
entities for tropical diseases (defined here as parasitic
diseases [malaria, African trypanosomiasis, Chagas’
disease, schistosomiasis, leishmaniasis, lymphatic
filariasis, onchocerciasis, intestinal nematode infections],
leprosy, dengue, Japanese encephalitis, trachoma, and
infectious diarrhoeal diseases) and tuberculosis. These
infectious diseases represent a substantial burden among
developing countries, and together account for 11·4% of
the global disease burden. We found that only 1% of the
1393 new chemical entities marketed between 1975 and
1999 were registered for these diseases: 13 for a tropical
disease indication, and three for tuberculosis (table 1).
Not unexpectedly, drug development outcomes closely
follow the existence of viable markets. US$307 million per
million DALYs is spent worldwide on non-infectious
respiratory diseases, compared with $3 million per million
DALYs for tropical diseases. Drugs for cardiovascular and
central-nervous-system diseases account for 35% of
worldwide pharmaceutical sales, and represent 28% of the
1393 new chemical entities. This imbalance is also shown
in the overall level of pharmaceutical industry investments
for research and development: of the $35·3 billion7
invested in 1999, 10·1% was spent on infectious diseases.
By contrast, estimates suggest that the total investment
(public and private sector) in drug research and
development for malaria, tuberculosis, leishmaniasis, and
African trypanosomiasis was less than $70 million.8
An average of 55·7 new chemical entities were
developed each year, with an innovation index averaging
Therapeutic areas Approved Disability-adjusted life-years (DALYs)† Proportion of NCEs by Drug sales 
NCEs Number World- High-income Low- and middle- worldwide DALY (millions of US$) 
1975–99* (106) wide (%) countries (%) income countries (%) sales, 1999‡ by DALY
Central nervous system 211 (15·1%) 159·46 11·5 23·5 10·5 15·1% 1·32 193
Cardiovascular 179 (12·8%) 143·02 10·3 18·0 9·7 19·8% 1·25 283
Cytostatics (neoplasms) 111 (8·0%) 84·87 6·1 15·8 5·2 3·7% 1·31 90
Respiratory (non-infectious) 89 (6·4%) 61·60 4·5 7·4 4·2 9·3% 1·44 307
Anti-infectives and antiparasitics§ 224 (16·1%) 409·08 29·6 4·2 31·8 10·3% 0·55 52
HIV/AIDS¶ 26 (1·9%) 70·93 5·1 0·9 5·5 1·5% 0·37 44
Tuberculosis|| 3 (0·2%) 28·19 2·0 0·1 2·2 0·2% 0·11 11
Tropical diseases (total)** 13 (0·9%) 130·35 9·4 0·3 10·2 0·2% 0·10 3
Malaria 4 (0·3%) 39·27 2·8 0·0 3·1 0·1% 0·10 5
Other therapeutic categories 579 (41·6%) 524·54 37·94 31·08 38·59 41·9% 1·10 163
Total 1393 (100%) 1382·56 100 100 100 100% 1·01 148
*Sources: IMS Health drug monitor 1999 (http://www.imshealth.com); EMEA and FDA data; reference 5. †Data from WHO World Health Report, 1999. ‡Total pharmaceutical
sales for 1999 was US$204 700 million (IMS health). Includes private pharmacy sales for all drug classes except anti-infectives and parasitics, which also include public
pharmacy sales. §Includes antibiotics, antituberculosis drugs, antivirals, vaccines, and immunoglobulins. ¶Including 20 AIDS antiviral drugs and six drugs for opportunistic
infections; atovaquone is also quoted under malaria. ||Pyrazinamide, rifabutin, rifapentine. **Benznidazole, nifurtimox (Chagas’ disease); albendazole (helminthic infection);
eflornithine (human African trypanosomiasis); artemether, atovaquone+proguanil, halofantrine, mefloquine (malaria); ivermectin (onchocerciasis); oxamniquine, praziquantel
(schistosomiasis) and two reformulations of already approved drugs: liposomal amphotericin B (leishmaniasis) and pentamidine (African trypanosomiasis). After 1999, two
new drugs were registered for malaria: artemether and artemether/lumefantrine.
Table 1: New chemical entities (NCEs) approved between 1975 and 1999 by drug class and relative to disease burden and drug sales
Period Number of Innovation NCEs listed NCEs listed in WHO 
approved index in 1999 EDL indicated for a 
NCEs WHO EDL neglected disease
1975–79 248 0·339 2* 0
1980–84 256 0·308 16† 6
1985–89 277 0·278 8‡ 4
1990–94 280 0·314 4§ 1
1995–99 332 0·324 7¶ 5
Total 1393 .. 37 16
5-year average 279 0·313 7 3
NCEs=new chemical entities. *Cisplatin, levothyroxine. †Aciclovir, benznidazole,
captopril, cimetidine, cetriaxone, clavulinic acid, factor VIII concentrate, factor
IX complex, iohexol, nifedipine, nifurtimox, oxamniquine, pentamidine,
praziquantel, pyrazinamide, testosterone enantate. ‡Albendazole, ceftazidine,
ciprofloxacine, fluconazole, ivermectin, halofantrine, mefloquine, zidovudine.
§Atenolol, ciclosporin, eflornithine, imipenem-cilastatin. ¶Liposomal
amphotericin B, artemether, atovaquone, etoposide, nevirapine, rifabutine,
rifapentine. Italics indicate approval for a neglected-disease indication.
Sources: EMEA and FDA data; 
IMS statistics; WHO essential drug list (EDL, available at
www.who.int/medicines/edl/edl11-alpha.html); reference 5.
Table 2: Innovation during 1975–99
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ment for all neglected diseases, six research and
development projects can be classified as mid-late
development projects, and an additional 12 early develop-
ment projects are ongoing. This number compares with
an estimated 2100 compounds in clinical development for
all other diseases during 1999–2000.7
There is no indication that drug development for
neglected diseases will significantly improve in the near
future. A recent study by the Drugs for Neglected
Diseases working group (an independent group
established by Médecins Sans Frontières to examine drug
development for neglected disease) and the Harvard
School of Public Health questioned the world’s top 
20 pharmaceutical companies on their research and
development activities for malaria, tuberculosis, African
trypanosomiasis, Chagas’ disease, and leishmaniasis. 
11 companies responded, representing 29% of the
worldwide pharmaceutical market for 2002. Of these
companies, seven reported spending less than 1% of their
research and development budget over the previous 
fiscal year on any of the five diseases, and eight spent
nothing on the three most neglected diseases (African
trypanosomiasis, Chagas’ disease, and leishmaniasis).8
Overall, the biggest advance in drug research and
development and new chemical entity outputs for
neglected diseases has been in malaria, for which four new
chemical entities have been approved between 1975 and
1999, and 18 projects were in clinical development in
2001. The new approaches to antimalarial therapies rely
mainly on artemisinin derivatives discovered in China in
the 1970s, which are particularly effective in combination
with other drugs in slowing the development and spread
of drug resistance. Malaria represents the largest
proportion of public and private research expenditures for
tropical diseases (includes research on drugs, vaccines,
environmental interventions, and vector-control
programmes) and accounted for 56% of the 1988–99
Tropical Disease Research (TDR) budget, 2% of the total
US National Institutes of Health budget, and 4% of the
UK Wellcome Trust’s budget.9 The other neglected
diseases are poor relatives when compared with malaria
(table 3). 
Moreover, the mean time for clinical development is
longer for neglected diseases than for other indications. In
the USA, the mean time for clinical development during
the 1990s was 8·8 years for neglected diseases, compared
with 5·4 years for other indications.10 The comparatively
poor performance is attributable to the low market
viability of these compounds, and hence suboptimum
funding compared with potentially more profitable
projects. Whereas the development of all 16 new chemical
entities for neglected diseases received at least some level
of public-sector support, this sector is also failing: thus far
there is no example of the public sector as applicant for a
drug registered for a neglected indication (although a
submission to the US, UK, and Swiss authorities made in
2001 by TDR for rectal formulation of artesunate is
awaiting assessment).
The data presented here quantify the degree of neglect
and poor outcome in terms of drugs to control the
infectious diseases that disproportionately affect
impoverished populations. Although substantial advances
in molecular biology and pathophysiology have been
made—including the ongoing genome sequencing of the
parasites that cause malaria, leishmaniasis, and African
trypanosomiasis—these advances are not translating into
new products directed at the needs of patients.11,12 More is
known and published on the biology of leishmania and
trypanosomes than any other parasite, yet virtually no
products result from this wealth of knowledge.13 This
absence is mainly a consequence of inadequate invest-
ment in drug research and development for neglected
Disease Early development* Mid–late development Studies with registered entities
Malaria Chlorproguanil/dapsone/artesunate (Liverpool Chlorproguanil/dapsone (TDR, GSK, Artemether/lumefantrine (Novartis)
University [UK], GSK, TDR, MMV) DFID, WHO)
Pyronaridine/artesunate (TDR, Shin Poong, Artesunate rectal (TDR, Knoll Sherer, Artesunate/mefloquine (WT, TDR, MSF)
MMV) Scanpharm, Novartis)
Modified side-chain chloroquine Tafenaquine (etaquine: WRAIR, GSK, NIH) Artesunate/sulfadoxine/pyrimethamine 
(Tulane University [TX, USA]) (TDR, MSF, IDA, WT)
Dihydroartemisinin (Artecef BV) .. Artesunate/amodiaquine (TDR, MSF)
Fosmidomycin (Jomaa Pharmaka GmbH, TDR) .. Dihydroartemisinin/piperaquine (Guangzhou 
University [China], WT, WHO)
Desbutyl halofantrine (GSK) .. Dihydroartemisinin/mefloquine 
(Thai Government, TDR)
.. .. Artesunate/atovaquone/proguanil (WT)
.. .. Azythromycin combinations (WRAIR, NIH, 
Pfizer)
Leishmaniasis Sitamaquine (WR6026: WRAIR, GSK) Paromomycin (TDR, IOWH, MSF, IDA) Amphotericin B liposomal (Cornell & Banaras 
(visceral) Hindu University [India])
.. Miltefosine oral (TDR, AstaMedica) ..
Onchocerciasis Moxidectin (TDR) .. Ivermectin/albendazole (TDR)
Oral eflornithine (Aventis, TDR) .. Ivermectin/levamisole (TDR)
.. .. Albendazole/levamisole (TDR)
.. .. Ivermectin/doxycycline (TDR, Nocht Institute 
[Germany])
Lymphatic .. .. Ivermectin/albendazole (TDR)
filariasis .. .. Ivermectin/doxycycline (TDR, Nocht Institute)
.. .. Albendazole/diethylcarbamazine (TDR)
Schistosomiasis Artemether (TDR) Praziquantel/albendazole (TDR)
Chagas’ disease .. .. ..
Leprosy .. Oxofloxacin/rifampicin (TDR) ..
Tuberculosis Moxifloxacin .. ..
Gatifloxacin .. ..
Sources: WHO, Special Programme for Research and Training in Tropical Diseases (TDR). GSK=GlaxoSmithKline; MMV=Medicines for Malaria Venture, Switzerland;
WT=Wellcome Trust, UK; MSF=Médecins Sans Frontières; WRAIR=Walter Reed Army Institute of Research, USA; IDA=International Dispensary Association,
Netherlands; IOWH=International One World Health; DFID=Department for International Development, UK; NIH=National Institutes of Health, USA. *No absolute
distinction can be made between early and mid–late development.
Table 3: Drugs under clinical development for a neglected-disease indication in 2001
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government purchasing power), there will be no incentive
to develop them further. In the USA, 39% of new
chemical entities in clinical development are abandoned
because profit prospects are poor.24
Orphan-type legislation is therefore unlikely to provide
the solution to drug development for tropical diseases. In
any case, whether the pharmaceutical industry—one of
the most profitable industrial sectors today25 thanks to
extended market monopolies—should be given further
market incentives is to be questioned. The ongoing debate
surrounding industry’s claim that drug research and
development is extremely costly,26 and the uncovering of
the pharmaceutical industry’s innovation deficit,27 lend
further weight to such concerns.
Another mechanism that has been mainly applied to
vaccines is differential pricing between industrialised and
developing countries, allowing research and development
investments to be recouped in wealthier countries so that
lower prices can be charged in developing countries (eg,
pricing at production costs plus a small margin).28
Whether differential pricing can be applied to drugs is
currently being explored, but it would be unlikely to offer
much for the most neglected diseases that exist exclusively
in poor countries.
In 1998, more than 90% of the worldwide
pharmaceutical production by value, and 97% of research
and development activities, occurred in developed
countries.29 With few exceptions, the countries concerned
with neglected diseases lack adequate capacity to
undertake research and development activities for
neglected diseases. To counter this polarity, building of
local research and development and production capacity
through technology transfer is being examined as a tool to
generate long-term solutions as well as economical
development. The transfer of capacities requires an
enabling environment at both the provider and the
receiver end—in most cases, the private sectors of
developed and developing countries. Capacity building
and technology transfer has been promoted for many
years by such groups as the United Nations Development
Programme,30 TDR, and the Drugs for Neglected
Diseases Working Group. It can be promoted via bilateral
and multilateral development cooperation, but priority-
setting must be well adapted to the specific needs and
capabilities of the concerned countries, who themselves
must place neglected diseases higher up the political
agenda. Emerging economies could be the first target of
action, and solutions for the poorest countries could be
grafted on successful drug production facilities in those
countries.
This issue of technology transfer inevitably leads to 
the consequences of the implementation of provisions 
of the World Trade Organisation TRIPS (Trade-Related
Intellectual Property Rights) agreement. Whether
intellectual property rights can significantly affect
technology transfer (which is included as an objective in
Article 7 of the TRIPS agreement) and foreign direct
investment towards developing countries is unclear.31
A broader question with respect to intellectual property
rights protection is how viable it is as a system for
stimulating research and development and delivering the
most needed medicines. The costs to national
governments of extended intellectual property protection
and subsidies need to be considered. Intellectual property
regimes are in essence a pull mechanism intended to
promote research and development. There is no
conclusive evidence that further strengthening of
intellectual property rights (through for example roaming
patent extensions—a proposal favoured by the
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diseases. For example, investment in research for malaria,
at $42 per fatal case, is at least 80 times lower than for
HIV/AIDS and 20 times lower than for asthma.14 The
other neglected diseases lag even further behind.
Current incentives and technology transfer
The pharmaceutical industry argues that research and
development is a “costly and risky activity”.15 This
argument is put forward to explain the lack of research
and development into diseases of the poor, and to justify
the high price of new chemical entities. Developed
countries offer viable market incentives for research and
development through individual purchasing power and
purchasing through government-run health insurance
programmes. In Europe, for instance, these mechanisms
cover two-thirds of drug costs for 80–100% of the
population16 as opposed to 35% in Latin America and less
than 8% in Africa.17 With public spending on drugs at
around $239 per head per annum in countries belonging
to the Organisation for Economic Cooperation and
Development (OECD), the pharmaceutical industry has a
strong incentive to develop drugs for this market. By
contrast, most developing countries spend less than $20
per year and per head on all health programmes (less than
$6 in sub-Saharan Africa, including drug expenditures18).
This situation results from a market too small to attract
private-sector investment in research and development for
the diseases that mainly affect developing countries.
Measures envisaged to overcome this limitation in both
public and private markets are either incentives devised to
encourage private investment towards the development of
new cost-effective drugs (often referred to as push and
pull mechanisms), or public-private partnerships.
Push mechanisms are incentives that operate upstream
during the research and development process, and involve
costs to the public sector without a guarantee that a viable
drug will be delivered (such as tax credits for and public
investment in research and development, which lower the
cost). Pull mechanisms operate downstream, and offer
public incentives for development of a product (examples
include patent extensions and advance purchase
commitments). In exchange for this increased market
attractiveness or market subsidy, private pharmaceutical
companies are expected to increase their research and
development efforts.19 There are examples of push and
pull mechanisms, or a blend of the two, being applied to
areas of the pharmaceutical sector with variable effects. 
Orphan drug legislation is an example of push and pull
elements combined, which uses a blend of tax credits,
market exclusivity, and intellectual property protection.
The US Orphan Drug Act, which grants market
exclusivity for rare diseases of national public-health
priority in the USA, is generally regarded as a domestic
success story.20 Drawing a parallel between rare and
neglected diseases drugs is tempting. However, orphan
legislation operates within a market logic: reasons for
success in the USA, are inapplicable in the countries
mainly affected by neglected diseases, and so far no drug
candidates for a neglected disease indication have been
developed and marketed through US and European
orphan legislations.21 Moreover, market prices for orphan
drugs are extremely high (the annual cost of life-long
treatment with alglucerase for Gaucher’s disease is about
$150 000 per patient22), whereas the average annual per-
head health-care expenditure in sub-Saharan Africa is
currently $6.23 Push mechanisms might contribute to fast-
track research and development or give a wealth of new
lead compounds through public investment. But if there is
no viable market for these candidate drugs (patient or
For personal use.  Only reproduce with permission from The Lancet Publishing Group.
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pharmaceutical industry) results in benefits to public
health. In the OECD countries, between the 1980s and
1990s, the effective patent life of drugs was extended by 
6 years as a result of several “patent term restoration”
measures that conferred a total average patent life of 
14 years from marketing (such as the Hatch-Waxman Act
of 1984 in the USA and the Supplementary Protection
Certificate of 1993 in Europe). But while the total
number of products registered increased slightly in the
same period, the mean innovation index remained
unchanged (table 2). Judging from the lack of research
and development for tropical diseases in the past 25 years,
market incentives provided by intellectual property rights
do not work when market prospects are poor or non-
existent.
Regulations are an important element in the research
and development process, and have been adapted by
Western regulatory authorities to respond better to specific
priority health needs. For example, fast-track registration
was successful in speeding up the delivery of medicines for
HIV/AIDS. Such measures result, in particular, in shorter
review times for drugs considered as responding to health
priorities: the mean approval time in the USA is 
11·8 months (ranging from 26·4 months for respiratory
agents to 4·6 months for AIDS antiretrovirals).32
In the West, drug regulation follows strict guidelines
defined by the International Conference on Harmonisation
of regulatory requirements for registration of pharma-
ceuticals (ICH). But neglected diseases are not a priority in
the West, and region and context-specific expertise and
regulatory capacity is therefore needed in countries where
these diseases are endemic so that review and registration
of novel compounds or new chemical entities can occur in
a way that is relevant to the priorities of disease-endemic
countries.
For example, malaria control has improved significantly
in some Asiatic countries because of the availability of
new and effective drugs, notably artemisinin derivatives,
registered in several disease-endemic countries. Yet
corresponding drug dossiers may not strictly conform to
ICH guidelines. Initiatives to harmonise drug regulation
at a regional level currently underway in southeast Asia
(ASEAN technical cooperation in pharmaceuticals) and
South America (MERCOSUL treaty) are examples of
initiatives that should be strengthened.
Double standards of drug quality, safety, and efficacy
are not acceptable, and standards set by WHO must be
adhered to as the minimum normative criteria. But
guidance on regulatory procedures based more on
technological advances than on nationally determined
health priorities are increasingly being applied, with the
net effect of inhibiting drug development capacity in the
developing world. Specific procedures should be designed
to allow for a better assessment of the risk-benefit ratio of
drugs for neglected diseases, allowing for speedier and
more effective drug development. 
Public-private partnerships
Public-private partnerships (PPPs) attempt to fill gaps in
the health needs of developing countries through the
establishment of public-private collaboration, networks,
and partnerships.33,34 The private sector includes for-
profit (pharmaceutical companies) and not-for-profit
(charities, foundations, and philanthropic institutions)
groups, whereas the public sector includes international
organisations, development and aid agencies, governments,
and academia.
Recently, PPPs have altered the international health
landscape, particularly in the pharmaceuticals sector, as a
new paradigm for drug development activities. They have
resulted from a gradual convergence of the private-for-
profit and public sectors (under pressure of international
organisations such as the World Bank), concerned
engagement by the not-for-profit sector, and the
pharmaceutical industry’s need to improve its image.
Traditional examples of public institutions working in
partnership with the private sector on individual drug
development projects include TDR and the US Walter
Reed Army Institute of Research (WRAIR). The
antimalarial drug mefloquine, for example, was
discovered by the WRAIR and later developed jointly with
industry and TDR. The PPP concept has more recently
evolved into more structured and product-based
collaborations, mainly for products that have already
reached advanced phases of development.
There were various examples of ad-hoc agreements
during the 1990s to develop drugs between TDR 
and WRAIR and drug companies, sometimes with
government-donor support. However, the progressive
withdrawal of the pharmaceutical industry from the
tropical-disease sector widens the gaps in the drug
development process, especially at the point of transition
between discovery and early development. To address
this problem, recent agreements between the public and
private sector also focus on the discovery process, for
example to access industry’s chemical libraries (such as
the agreement between the Japanese pharmaceutical
industry association, the Japanese government, and
TDR). Most of these types of partnerships have
depended on a coincidence of priorities among partners
who each contribute assets or funds to develop specific
products.
The most recent trend favours disease-based initiatives,
as exemplified by the Medicines for Malaria Venture
(which accounts for most of today’s antimalarial drug
development projects) and the Global Alliance for
Tuberculosis. Both initiatives focus mainly on converting
drug candidates into registered entities using a social
venture capital model funded by the public and
philanthropic sectors. They are managed as not-for-profit
ventures, operate in collaboration with several partners
ranging from the traditional pharmaceutical industry to
corporations, academia, and development agencies,35 and
rely on business drug development models and a medium-
term secured budget including newer sources of funding
(such as the Gates Foundation). 
Industry has played a part in the establishment of 
these new ventures, is represented through their boards,
and is a development partner, contributing both facilities
and assets and receiving funds. However, company
engagement is limited: of the 14 active or planned
projects of the Medicines for Malaria Venture, five 
still have no industrial partner, and six companies 
are involved in the remaining nine projects
(GlaxoSmithKline alone accounts for three).
Much hope is placed in public-private partnerships,
but it is too early to say how successful these initiatives
will be.34 Moreover, developing a drug is one thing, but
consideration must also be given to ensuring equitable
access. Engagement with an industry whose strategy has
so far largely been to maximise profit in the West, rather
than establish an equitable pricing policy worldwide,7
requires careful management of intellectual property.
Donor agencies, for their part, must do more to assist in
drug procurement: current financial pledges to the
Global Fund for AIDS, TB and Malaria, at less that one
fifth of the estimated requirement, indicate that much
greater political will is required.
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obligations under international agreements. The public
sector—ie, the main buyer of pharmaceuticals—provides
the private sector with patent incentives for innovation,
but has little say over the research agenda. Governments
can and do oblige industry to do necessary research in
other sectors. A neglected-disease research obligation
could be framed that would require industry to reinvest a
percentage of pharmaceutical sales into neglected disease
research and development, either directly or through
public programmes.
For the most neglected diseases such as African
trypanosomiasis or leishmaniasis, which might not
account for much of the global disease burden, but which
represent a significant disease burden in affected
countries, a new approach is needed. The Drugs for
Neglected Diseases working group is currently exploring
the feasibility of an international not-for-profit initiative
that would focus on drug development projects for the
most neglected diseases. Such an initiative would remove
the process of researching and developing life-saving
drugs from a market-driven logic. Without a shift to
needs-driven research and development, the needs of
millions in the developing world will continue to be
ignored.
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The tip of the iceberg?
J Eikelboom
Uses of error
Royal Perth Hospital, Perth 6847, Australia (J Eikelboom MD)
I was a medical student on my first clinical rotation and
the patient was a confused elderly male who needed a
urinary catheter. The houseman gratefully accepted my
offer of assistance and disappeared to attend to other
duties. I should have realised that something was amiss
when the patient groaned during inflation of the balloon.
However, I reasoned that a 16 French catheter couldn't
possibly be comfortable, and ignored the signs. Several
hours later, the consultant noticed blood seeping around
the catheter, and ordered deflation of the intrauretheral
balloon.
I was a medical intern in orthopaedic surgery, and one
of my charges was an elderly male who had undergone
surgery for a fractured neck of femur. For three
successive nights an increasingly irate senior houseman
was asked to review him for recurrent breathlessness.
However, by the next morning, his symptoms had
invariably resolved and the ward round barely slowed
long enough to confirm that his wound was healing
satisfactorily. I am still grateful that my patient survived
his sojourn on the orthopaedic ward long enough to be
transferred to a medical rehabilitation unit where his left
ventricular failure was finally treated. While inexperience
contributed to these errors, fatigue played a role in the
next. I was awoken by a telephone call at 4 am to hear
that the respiratory failure of a woman in her forties with
pulmonary graft-versus-host-disease was getting worse. I
ordered a chest radiograph and an increase in the oxygen
flow rate before going back to sleep. The radiograph was
not reviewed until several hours later, by which time 
the pneumomediastinum had caused irremediable
deterioration. I am uncertain whether earlier invertention
would have postponed her demise, as she died
subsequently from respiratory failure. The need for
adequate supervision, a more effective referral system,
and improvements in working hours is self-evident.
